NCT06989359Phase 2Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Study sponsor: ADARx Pharmaceuticals, Inc. · ADRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2030-04-30Estimated
Enrollment · participants85Estimated
Source updated2026-11-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - 36 months. After: Measure: Evaluate the safety and tolerability of ADX-038 Description: Incidence and severity of TEAEs Time frame: Length of study - From Day 1 through Month 24.

Planned enrollment increased by 40 participants

Before: 45 participants (planned). After: 85 participants (planned).

Primary completion date changed

Before: 31 Dec 2028. After: 30 Apr 2030.

Check registry source

· 1 field changed

Primary completion date changed

Before: Jul 2027. After: 31 Dec 2028.

Check registry source

· 2 fields changed

Planned enrollment increased by 15 participants

Before: 30 participants (planned). After: 45 participants (planned).

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source